Patents by Inventor Larry Wendell Hardy

Larry Wendell Hardy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
    Patent number: 11186564
    Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: November 30, 2021
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Scott P. Brown, Lee W. Herman
  • Metabotrophic glutamate receptor 5 modulators and methods use thereof
    Patent number: 10640510
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 5, 2020
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF
    Publication number: 20200079778
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: December 6, 2018
    Publication date: March 12, 2020
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 10562878
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: February 18, 2020
    Assignee: SUNOVION PHARAMCEUTICALS INC.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campell
  • Metabotrophic glutamate receptor 5 modulators and methods of use thereof
    Patent number: 10533000
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: January 14, 2020
    Assignee: Sunovion Pharmaceuticals, Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat
  • DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS
    Publication number: 20190194163
    Abstract: Compounds of formula I: are disclosed, as are pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disorders in a patient in need are also disclosed. Such disorders include depression, bipolar disorder, pain, schizophrenia, obsessive compulsive disorder, addiction, social disorder, attention deficit hyperactivity disorder, an anxiety disorder, autism, a cognitive impairment, or a neuropsychiatric symptom such as apathy, depression, anxiety, psychosis, aggression, agitation, impulse control disorders, and sleep disorders in neurological disorders such as Alzheimer's and Parkinson's diseases.
    Type: Application
    Filed: August 4, 2016
    Publication date: June 27, 2019
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L.R. HEFFERNAN, Larry Wendell HARDY, Scott P. BROWN, Lee W. HERMAN
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF
    Publication number: 20190135815
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: December 6, 2018
    Publication date: May 9, 2019
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
    Publication number: 20190055204
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: August 21, 2018
    Publication date: February 21, 2019
    Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Metabotrophic glutamate receptor 5 modulators and methods use thereof
    Patent number: 10196399
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: February 5, 2019
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
    Patent number: 10077243
    Abstract: Provided herein are compounds of formula (I): and pharmaceutical compositions thereof, useful for the treatment of disorders mediated by metabotropic glutamate receptor 5.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: September 18, 2018
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Larry Wendell Hardy, Michele L. R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
    Publication number: 20180230120
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Application
    Filed: December 8, 2017
    Publication date: August 16, 2018
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPELL
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF
    Publication number: 20180037585
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: June 16, 2017
    Publication date: February 8, 2018
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 9868718
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: January 16, 2018
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Larry R. Bush, Jianguo Ma, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, John E. Campbell
  • PHENYL SUBSTITUTED CYCLOALKYLAMINES AS MONOAMINE REPUTAKE INHIBITORS
    Publication number: 20170204050
    Abstract: Phenyl-substituted cyclohexylamine derivatives and methods for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Application
    Filed: January 30, 2017
    Publication date: July 20, 2017
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Jianguo MA, Seth RIBE, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, Rudy SCHREIBER, Kerry L. Spear
  • Metabotrophic glutamate receptor 5 modulators and methods of use thereof
    Patent number: 9708331
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: February 2, 2016
    Date of Patent: July 18, 2017
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
    Patent number: 9586888
    Abstract: Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat/prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: March 7, 2017
    Assignee: SUNOVION PHARMACEUTICALS INC.
    Inventors: Liming Shao, Fengjiang Wang, Scott Christopher Malcolm, Michael Charles Hewitt, Jianguo Ma, Seth Ribe, Mark A. Varney, Una Campbell, Sharon Rae Engel, Larry Wendell Hardy, Patrick Koch, Rudy Schreiber, Kerry L. Spear
  • METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS OF USE THEREOF
    Publication number: 20160251359
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Application
    Filed: February 2, 2016
    Publication date: September 1, 2016
    Inventors: Michele L.R. Heffernan, Larry Wendell Hardy, Frank Xinhe WU, Lakshmi D. Saraswat, Kerry L. Spear
  • Metabotrophic glutamate receptor 5 modulators and methods of use thereof
    Patent number: 9260452
    Abstract: Compounds that modulate GluR5 activity and methods of using the same are disclosed.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: February 16, 2016
    Assignee: Sunovion Pharmaceuticals Inc.
    Inventors: Michele L. R. Heffernan, Larry Wendell Hardy, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear
  • CYCLOALKYLAMINES AS MONOAMINE REUPTAKE INHIBITORS
    Publication number: 20150126511
    Abstract: The invention relates to novel cyclohexylamine derivatives and their use in the treatment and/or prevention of central nervous system (CNS) disorders, such as depression, anxiety, schizophrenia and sleep disorder as well as methods for their synthesis. The invention also relates to pharmaceutical compositions containing the compounds of the invention, as well as methods of inhibiting reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine from the synaptic cleft and methods of modulating one or more monoamine transporter.
    Type: Application
    Filed: September 30, 2014
    Publication date: May 7, 2015
    Inventors: Liming SHAO, Fengjiang WANG, Scott Christopher MALCOLM, Michael Charles HEWITT, Larry R. BUSH, Jianguo MA, Mark A. VARNEY, Una CAMPBELL, Sharon Rae ENGEL, Larry Wendell HARDY, Patrick KOCH, John E. CAMPBELL
  • COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF
    Publication number: 20140349992
    Abstract: Provided herein are compounds and methods of synthesis thereof. The compounds set forth herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, neurodegenerative disorders, neuropsychiatric disorders, disorders of cognition, learning or memory, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds set forth herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.
    Type: Application
    Filed: June 9, 2014
    Publication date: November 27, 2014
    Applicant: Sunovion Pharmaceuticals Inc.
    Inventors: Larry Wendell Hardy, Michele L.R. Heffernan, Frank Xinhe Wu, Lakshmi D. Saraswat, Kerry L. Spear